CoChat

Rapid Delivery of Nanobodies/VHHs into Living Cells via Expressing In Vitro-Transcribed mRNA

Zhou, Xuechen, Hao, Rui, Chen, Chen, Su, Zhipeng, Zhao, Linhong, Luo, Zhuojuan, Xie, Wei · 2020 · Molecular Therapy - Methods & Clinical Development
Cited by 26

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtm.2020.01.008

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • mRNA-based therapeutics--developing a new class of drugs

    Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · cited 1×

    “So the development of IVTmRNA-based therapeutics has gained broad attention.(14)One of themain uses of IVTmRNA is to deliver protein into living cells, but recently, nanobodies/VHHs have been expanded toward mining from traditional antibodies.”
    Background
  • Expression of therapeutic proteins after delivery of chemically modified mRNA in mice

    Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733 · cited 3×

    “In order to increase the stability of mRNA, there is an inclusion of chemically modified nucleotides.33 (1) Kormann et al.22 have shown that the replacement of only 25% of uridine and cytidine residues by 2-thiouridine and 5-methyl-cytidine suffices to increase mRNA stability, as well as to reduce the activation of in…”
    BackgroundMethodInfluential
  • Database for mRNA Half-Life of 19 977 Genes Obtained by DNA Microarray Analysis of Pluripotent and Differentiating Mouse Embryonic Stem Cells

    Sharova, L. V., Sharov, A. A., Nedorezov, T., Piao, Y., Shaik, N., & Ko, M. S. H. (2009) · DNA Research · doi:10.1093/dnares/dsn030 · Cited by 591 · cited 1×

    “Recently, data on mRNA half lives and the corresponding UTR sequences have been published.(37,38)”
    Background
  • Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes

    Veiga, N., Goldsmith, M., Granot, Y., Rosenblum, D., Dammes, N., Kedmi, R., Ramishetti, S., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-06936-1 · Cited by 308 · cited 1×

    “In addition, IVT mRNA-based therapeutics, unlike plasmids, do not need to be integrated into the genome and do not have a risk of insertional mutation of genomics.(32) For most pharmaceutical applications, it is also an advantage that IVT mRNA is only transiently active and completely degraded via metabolic pathways.”
    Background
  • An RNA toolbox for cancer immunotherapy

    Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.132 · Cited by 229 · cited 1×

    “Compared to intracellular delivery expressed by DNA, mRNA vaccines represent a promising alternative to conventional vaccine approaches due to their high potency, capacity for rapid development, as well as potency for low-cost manufacture and safe administration.(30,31) Plasmids need to be situated in the nucleus and…”
    Background
  • Small Molecule Targeted Recruitment of a Nuclease to RNA

    Costales, M. G., Matsumoto, Y., Velagapudi, S. P., & Disney, M. D. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01233 · Cited by 212 · cited 1×

    “In vitro-transcribed (IVT) mRNA is an ideal carrier to deliver genetic information into living cells.(13) Over the last years, many interesting techniques of IVT mRNA were proposed and shown to be useful for many applications.”
    Background
  • RNA binding protein/RNA element interactions and the control of translation

    Pichon, X., A. Wilson, L., Stoneley, M., Bastide, A., A King, H., Somers, J., & E Willis, A. (2012) · Current Protein & Peptide Science · doi:10.2174/138920312801619475 · Cited by 144 · cited 1×

    “It has been shown that a prolongation of the poly(A) tail to 120 nt has beneficial effects on protein expression, assumingly because of the protective effect of longer poly(A) tails; mRNAs with poly(A) tails shorter than 50 nt are claimed not to be translated at all.(20,34) (3) CappedmRNA can increase the translated e…”
    Background

Show all 7 references

Research works printed but not linked: 35

  1. Strohl, 2018, Current progress in innovative engineered antibodies, Protein Cell, 9, 86, 10.1007/s13238-017-0457-8 · DOI · Paper page
  2. Leavy, 2010, Therapeutic antibodies: past, present and future, Nat. Rev. Immunol., 10, 297, 10.1038/nri2763 · DOI · Paper page
  3. Chan, 2010, Therapeutic antibodies for autoimmunity and inflammation, Nat. Rev. Immunol., 10, 301, 10.1038/nri2761 · DOI · Paper page
  4. Carter, 2018, Next generation antibody drugs: pursuit of the ‘high-hanging fruit’, Nat. Rev. Drug Discov., 17, 197, 10.1038/nrd.2017.227 · DOI · Paper page
  5. Trenevska, 2017, Therapeutic Antibodies against Intracellular Tumor Antigens, Front. Immunol., 8, 1001, 10.3389/fimmu.2017.01001 · DOI
  6. Marschall, 2011, Targeting antibodies to the cytoplasm, MAbs, 3, 3, 10.4161/mabs.3.1.14110 · DOI
  7. Stocks, 2005, Intrabodies as drug discovery tools and therapeutics, Curr. Opin. Chem. Biol., 9, 359, 10.1016/j.cbpa.2005.06.003 · DOI
  8. Muyldermans, 2001, Single domain camel antibodies: current status, J. Biotechnol., 74, 277
  9. Hamers-Casterman, 1993, Naturally occurring antibodies devoid of light chains, Nature, 363, 446, 10.1038/363446a0 · DOI · Paper page
  10. Zuo, 2017, Institute collection and analysis of Nanobodies (iCAN): a comprehensive database and analysis platform for nanobodies, BMC Genomics, 18, 797, 10.1186/s12864-017-4204-6 · DOI
  11. Leslie, 2018, Small but mighty, Science, 360, 594, 10.1126/science.360.6389.594 · DOI
  12. Rothbauer, 2006, Targeting and tracing antigens in live cells with fluorescent nanobodies, Nat. Methods, 3, 887, 10.1038/nmeth953 · DOI · Paper page
  13. Kubala, 2010, Structural and thermodynamic analysis of the GFP:GFP-nanobody complex, Protein Sci., 19, 2389, 10.1002/pro.519 · DOI · Paper page
  14. Maier, 2015, Real-time analysis of epithelial-mesenchymal transition using fluorescent single-domain antibodies, Sci. Rep., 5, 13402, 10.1038/srep13402 · DOI
  15. Herrmann, 2007, Intermediate filaments: from cell architecture to nanomechanics, Nat. Rev. Mol. Cell Biol., 8, 562, 10.1038/nrm2197 · DOI · Paper page
  16. Kawaguchi, 2003, The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress, Cell, 115, 727, 10.1016/S0092-8674(03)00939-5 · DOI · Paper page
  17. Johnston, 1998, Aggresomes: a cellular response to misfolded proteins, J. Cell Biol., 143, 1883, 10.1083/jcb.143.7.1883 · DOI · Paper page
  18. Moore, 2005, From birth to death: the complex lives of eukaryotic mRNAs, Science, 309, 1514, 10.1126/science.1111443 · DOI · Paper page
  19. Mignone, 2005, UTRdb and UTRsite: a collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs, Nucleic Acids Res., 33, D141, 10.1093/nar/gki021 · DOI · Paper page
  20. Cheever, 2009, The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research, Clin. Cancer Res., 15, 5323, 10.1158/1078-0432.CCR-09-0737 · DOI · Paper page
  21. Freund, 2013, Targeting endogenous nuclear antigens by electrotransfer of monoclonal antibodies in living cells, MAbs, 5, 518, 10.4161/mabs.25084 · DOI
  22. Kimura, 2015, Visualizing posttranslational and epigenetic modifications of endogenous proteins in vivo, Histochem. Cell Biol., 144, 101, 10.1007/s00418-015-1344-0 · DOI
  23. Prochiantz, 2000, Messenger proteins: homeoproteins, TAT and others, Curr. Opin. Cell Biol., 12, 400, 10.1016/S0955-0674(00)00108-3 · DOI · Paper page
  24. Sánchez-Navarro, 2017, Cytosolic delivery: Just passing through, Nat. Chem., 9, 727, 10.1038/nchem.2837 · DOI
  25. Dinca, 2016, Intracellular Delivery of Proteins with Cell-Penetrating Peptides for Therapeutic Uses in Human Disease, Int. J. Mol. Sci., 17, 263, 10.3390/ijms17020263 · DOI · Paper page
  26. Kristensen, 2016, Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos, Int. J. Mol. Sci., 17, 185, 10.3390/ijms17020185 · DOI · Paper page
  27. Pardi, 2018, mRNA vaccines - a new era in vaccinology, Nat. Rev. Drug Discov., 17, 261, 10.1038/nrd.2017.243 · DOI · Paper page
  28. Karikó, 2007, Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development, Curr. Opin. Drug Discov. Devel., 10, 523
  29. Pesole, 2000, The untranslated regions of eukaryotic mRNAs: structure, function, evolution and bioinformatic tools for their analysis, Brief. Bioinform., 1, 236, 10.1093/bib/1.3.236 · DOI · Paper page
  30. Barrett, 2012, Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements, Cell. Mol. Life Sci., 69, 3613, 10.1007/s00018-012-0990-9 · DOI · Paper page
  31. ’t Hoen, 2011, mRNA degradation controls differentiation state-dependent differences in transcript and splice variant abundance, Nucleic Acids Res., 39, 556, 10.1093/nar/gkq790 · DOI · Paper page
  32. Peyvandi, 2016, Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura, N. Engl. J. Med., 374, 2497, 10.1056/NEJMoa1505533 · DOI · Paper page
  33. Zhang, 2017, Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade, Cell Discov., 3, 17004, 10.1038/celldisc.2017.4 · DOI · Paper page
  34. Riedl, 2008, Lifeact: a versatile marker to visualize F-actin, Nat. Methods, 5, 605, 10.1038/nmeth.1220 · DOI · Paper page
  35. Storrie, 1998, Recycling of golgi-resident glycosyltransferases through the ER reveals a novel pathway and provides an explanation for nocodazole-induced Golgi scattering, J. Cell Biol., 143, 1505, 10.1083/jcb.143.6.1505 · DOI · Paper page

Cited by

Metadata

Authors
Zhou, X., Hao, R., Chen, C., Su, Z., Zhao, L., Luo, Z., & Xie, W.
Venue
Molecular Therapy - Methods & Clinical Development
Publisher
Elsevier BV
Published
2020-06
Volume
17
Pages
401-408
ISSN
2329-0501
Cited by
26
References
7
Language
en
Licence
Funders
National Natural Science Foundation of China (81570743, 81303019)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.